Objectives: To evaluate the risk for urological complications after kidney transplantation at a single medical center in Japan. Methods: In the present study, 408 kidney recipients (255 men, 153 women) were enrolled. There were 349 living and 59 deceased donors. The average age of the recipients was 42.5 AE 13.5 years, and the average pretransplant dialysis period was 71.8 AE 88.2 months. Ureteroneocystostomy was carried out on 347 patients, and ureteroureterostomy on 61 patients. We investigated the relationship between pretransplant duration of dialysis and bladder capacity, and examined the risk factors for urological complication. We also evaluated the incidence of vesicoureteral reflux in 191 recipients who underwent ureteroneocystostomy during transplantation. Results: The preoperative duration of dialysis therapy showed a significant negative correlation with bladder capacity (R 2 = 0.33, P < 0.001). The overall urological complication rate was 3.4% (14 patients), including urinary leakage (12 patients) and ureteral stricture (two patients). Univariate analysis showed that atrophic bladder, longterm dialysis therapy, deceased donor and ureteroureterostomy were associated with a higher incidence of urological complications (odds ratio 8. 05, 4.43, 3.42 and 3.35; P < 0.01, P = 0.01, P = 0.04 and P = 0.04, respectively). Furthermore, multivariate analysis showed that atrophic bladder was the only significant factor associated with urological complications (odds ratio 10.37; P = 0.01). Among 191 recipients, vesicoureteral reflux was observed in 32 (16.8%). The incidence of vesicoureteral reflux was significantly higher in patients with atrophic bladder. Conclusions: Bladder atrophy in renal transplant recipients after long-term dialysis therapy is associated with a higher risk of urological complications.
Introduction
UCs are sometimes inevitable after KT, and are associated with significant morbidity and mortality. The most frequent UCs related to KT surgery are urinary leakage, ureteral stricture and VUR. Recent improvements in surgical techniques and materials have significantly reduced the risk of post-transplant UCs; the current incidence of UCs among kidney transplant patients is reported to be less than 10%. [1] [2] [3] [4] [5] [6] In Japan, an extreme shortage of donors has forced patients with end-stage kidney disease to undergo long-term DT. Most of these patients are placed on hemodialysis rather than peritoneal dialysis. Long-term DT results in severe atrophy of the bladder as a result of prolonged disuse. After successful KT, the bladder usually hypertrophies and recovers its normal function. 7, 8 However, ureteral re-implantation of a severely atrophic bladder is surgically challenging. Regardless of the technique utilized, the procedure can be hazardous and has the potential to increase the risk of UCs in kidney transplant recipients.
Several recipient/donor characteristics and surgical techniques have been identified as risk factors for UC after KT, with bladder atrophy related to long-term DT being one of them.
3,4,6,9 However, few reports have described the relationship between UC and bladder capacity; additionally, these studies were too small to be conclusive. 10 ,11 Therefore, we retrospectively evaluated the incidence and risk factors for UC after KT in 408 recipients from a single kidney transplant center in Japan. Our study population included 64 patients with atrophic bladder related to long-term DT.
Methods

Patient data
We reviewed the medical records of all patients who underwent KT from 1996 to 2011 at Sapporo City General Hospital (n = 415). Our study focused on 408 patients, excluding seven patients whose graft function was lost within 1 year of transplantation. The characteristics of the study population are shown in Table 1 . We analyzed the relationship between the bladder capacity and pretransplant duration of DT. We also analyzed the type, incidence, treatment and risk factors of UC within 1 year after transplantation. Furthermore, we evaluated the relationship between bladder capacity and the incidence of postoperative VUR. The recipients received calcineurin inhibitors (tacrolimus or cyclosporine), antimetabolites (mycophenolate mofetil or azathioprine) and corticosteroids as immunosuppression therapy. Starting in 2002, some patients also received basiliximab for induction therapy. This study was approved by the Ethical Review Committee of Sapporo City General Hospital.
Definition of atrophic bladder and measurement of bladder capacity
We defined atrophic bladder as <50 mL of bladder capacity. We carried out a cystography on all recipients before transplantation from 1996 to 2008 to evaluate bladder capacity (method 1). From 2009 onwards, bladder capacity was measured using a urethral catheter at a hydrostatic pressure of 15 cmH 2 O under general anesthesia just before surgery (method 2). A total of 22 patients were evaluated using both methods. The bladder capacity measured using method 1 was 195 AE 121 mL, compared with 162 AE 96 mL with method 2. There was no significant difference in bladder capacity between the two methods ( Fig. 1) .
Procedure of ureteral anastomosis
UCS was carried out using a modified Lich-Gregoir technique (the length of submucosal tunnel: 3 cm) for 347 patients and UUS for 61 patients. Ureteral stents were used in 68 recipients: seven in UCS, and 61 in UUS. The ureteral stents were removed at 1-2 weeks post-transplantation. The decision for surgical methods and ureteral stent placement was based on the individual surgeon's practice and his/her intraoperative assessment. A Foley catheter was used to drain the bladders of all patients for at least 4 days post-transplantation.
Definition of urinary complications
For the present study, symptomatic urinary leakage or urinary stricture requiring intervention within 1 year of transplantation were defined as UC. Bladder capacity in 22 patients, evaluated using two different methods. The pretransplant bladder capacity measured by cystography without anesthesia (method 1) was 195 AE 121 mL, and that measured by a urethral catheter at 15 cmH 2 O under general anesthesia just before surgery (method 2) was 162 AE 96 mL. There is no significant difference in bladder capacity between these two methods.
Evaluation of postoperative VUR
Among 347 recipients who underwent UCS at transplantation, 191 were evaluated for the presence of VUR by voiding cystourethrography, which was taken on day 4 post-transplant routinely and when we suspected VUR based on urinary tract infection episodes or pathological findings of graft biopsy as well.
Statistical analysis
Statistical significance between the two groups of parametric data was evaluated using the Student's t-test. Pearson's coefficient was used for the correlation analysis of preoperative DT duration and bladder capacity. The association between categorical variables was tested using the v 2 -test. Fisher's exact test was used when appropriate. Only significant variables from the univariate analyses were used in logistic regression analyses to determine the independent risk factors for UC after KT. Statistical analysis was carried out with JMP 12.0.1 (SAS Institute, Cary, NC, USA). A P-value of <0.05 was considered statistically significant.
Results
Relationship between pretransplant duration of dialysis and bladder capacity
First, we analyzed the relationship between bladder capacity and pretransplant duration of DT. Pretransplant duration of DT showed a significant negative correlation with bladder capacity. Bladder capacity gradually decreased when the pretransplant duration of DT increased (Fig. 2a , R 2 = 0.33, P < 0.001). Furthermore, the rate of atrophic bladder dramatically increased in patients who had undergone >10 years of DT (Fig. 2b, <1 years: 0%, 2-5 years: 3.3%, 6-9 years: 8.8%, >10 years: 56%, P < 0.001).
UC and management
Of the 408 patients studied, 14 (3.4%) UCs were observed. Table 2 summarizes the UCs and treatments. Urinary leakage occurred in 12 cases: five cases that underwent UUS, and seven cases that underwent UCS. In the UUS group, one patient was treated with a ureteral stent and two with percutaneous nephrostomy. Two patients required further surgical intervention; one patient underwent UUS twice, and one underwent UCS. In the UCS group, one patient was treated with re-insertion of an indwelling Foley catheter, and six patients required UCS. Anastomosis stricture occurred in two patients, both of whom required UCS. All 14 cases of urinary complication did not lose their graft and recovered without permanent urinary tract damage after treatment.
Risk factors for UCs
Univariate analyses of risk factors for UCs are shown in Table 3 . Atrophic bladder, long-term DT, deceased donor and UUS were associated with a higher incidence of UCs (odds ratio 8.05, 4.43, 3.42 and 3.35; P < 0.01, P = 0.01, P = 0.04 and P = 0.04, respectively). The incidence of UC was not associated with recipient age, recipient sex, donor age, donor sex or ureteral stent placement. Multivariate analysis showed that atrophic bladder was the only independent factor associated with UC after KT (odds ratio 10.37; P = 0.01; Table 3 ). Next, we analyzed the incidence of UC among the patients with atrophic bladder to evaluate which surgical procedures were best for atrophic bladder recipients. We found that there was no significant difference in the risk for UC between UCS and UUS when it comes to atrophic bladder patients. Furthermore, there was no correlation between the incidence of UC and the use of ureteral stent in these patients (Table 4) .
Association between bladder capacity and postoperative VUR Finally, we compared the incidence of postoperative VUR in relation to bladder capacity. Among the 347 recipients who underwent UCS during transplantation, 191 were evaluated for the presence of VUR. Of these, VUR was observed in 32 (16.8%) patients. Ureteral stenting was not carried out for all 191 patients. Among the 32 patients who developed VUR, 17 VURs were observed 4 days after surgery. Of the 17 recipients, 11 were re-evaluated for the presence of VUR 5.4 AE 0.9 years post-transplantation; of these, VUR remained in 10 patients. Furthermore, seven of the 10 patients dramatically increases in patients receiving >10 years of DT (<1 years: 0%, 2-5 years: 3.4%, 6-9 years: 8.0%, >10 years: 56.6%, P < 0.001).
developed pyelonephritis after transplantation. The incidence of VUR was significantly higher in patients with atrophic bladder (bladder capacity <50 mL) than in patients with a bladder capacity of 50 mL or more (P < 0.001; Fig. 3 ). This result suggests that atrophic bladder is also a risk factor for VUR.
Discussion
An extreme shortage of donors has forced many patients in Japan with end-stage kidney disease to undergo long-term dialysis. As such, we sometimes carry out KT on patients with long-term DT. In the present study, 99 (24%) patients had undergone >10 years of DT before their KT. Long-term DT is known to cause complications, such as arterial stiffness, cardiovascular disease and abnormal bone metabolism. Several studies reported that successful KT minimizes these DT-related complications. [12] [13] [14] Atrophic bladder could be one of the complications related to long-term DT. Atrophic bladder is one of the potential complications related to long-term DT. Although bladders usually recover their capacity and function after KT, patients with atrophic bladders might be at risk of developing UC post-transplant as a result of difficulties in ureteral re-implantation. 7, 8 Additionally, many donor/ recipient factors and surgical techniques contribute to the development of UC after KT. 3, 4, 6, 9 However, few reports have described the relationship between UC and bladder capacity.
An earlier small study reported that atrophic bladder is associated with an increased risk for UC. 10 That study compared 20 recipients with long-term DT (>15 years) with 20 control recipients (DT period: <5 years). Pretransplant bladder capacity of long-term DT patients was significantly smaller than that of the control group. The incidence of UC in long-term DT patients was also higher than in controls. More recently, Chun et al. reported the incidence of UC in 23 recipients with atrophic bladders, and compared them with 322 recipients with normal bladders. 11 The incidence of UC was comparable between the two groups: 4.3% (1/23) in the atrophic bladder group, and 0.006% (2/322) in the control group. Wu et al. compared the incidence of UC among 41 kidney recipients with long-term DT (>10 years) with 31 recipients without pretransplant DT. 15 Although there was no difference in the incidence of UC between the two groups, they did not evaluate the bladder capacity of their patients. Atrophic bladder as a risk factor for UC has been controversial. However, the sample sizes of the studies described above were too small to produce reliable results. In the present study, the overall incidence of UC was 3.4%, which is comparable with previous studies, whereas the incidence of UC was as high as 12.5% in those with atrophic bladder. [1] [2] [3] [4] [5] [6] Furthermore, multivariate analysis showed that atrophic bladder was the single risk factor for UC. The present study is the first to report on a large enough number of patients to clarify this issue.
Although most surgeons carry out UCS and sometimes utilize UUS in the treatment of UC, few reports have evaluated the effectiveness of UUS as the initial procedure during transplant. Faenza et al. compared the incidence of UCs between UCS and UUS in 894 kidney recipients, and found no significant difference in the occurrence of UCs between these two procedures. 16 In contrast, the risk of postoperative urinary tract infection was significantly lower in UUS compared with UCS. Therefore, they suggested that UUS is an effective initial procedure during KT. In the present study, we carried out UUS on 61 recipients (15%) as initial anastomosis. We believed that UCS carries a much higher risk for UC than UUS, especially in recipients with atrophic bladders; therefore, 73% (47/64) of patients with atrophic bladder underwent UUS in the present study. However, the incidence of UC was similar between the two procedures in patients with atrophic bladders. The multivariate analysis showed that urinary complications were not associated with the ureteral anastomosis procedure. Small bladder capacity does not directly cause UC in UUS patients. However, a previous study showed that disused ureters significantly decreased their internal volume compared with normal ureters. 17 Patients with disused bladders are likely to have disused ureters too; therefore, we can assume that it would be difficult to carry out UUS on these patients as well. In terms of postoperative VUR, the incidence was significantly higher in patients with atrophic bladders. This could be contributed to by the difficulty in creating an adequate length of submucosal tunnel to prevent VUR. The incidence of VUR in native ureterovesical junctions of patients with atrophic bladders who have recovered their normal bladder capacity appears to be comparable with that of the general population, which is approximately 1%. 18 Although we did not evaluate the presence of VUR in patients who underwent UUS, the risk of VUR seems to be much higher in UCS patients compared with UUS patients, especially in those with atrophic bladders. Therefore, we recommend the use of UUS in patients with atrophic bladders in order to reduce the incidence of post-transplant VUR.
Although many reports and randomized trials suggest that the placement of a ureteral stent reduces the risk for UC, we found that there was no correlation between the incidence of UC and the use of ureteral stent among patients with atrophic bladders. [19] [20] [21] [22] We could not conclude whether stents reduced the risk for UC in atrophic bladder patients, as the placement of a ureteral stent was up to each surgeon's discretion.
We also evaluated the relationship between the pretransplant duration of DT and bladder capacity in all participants, in order to elucidate the trends in loss of bladder capacity. Bladder capacity significantly decreased with continued dialysis. Specifically, the rate of bladder atrophy (bladder capacity <50 mL) dramatically increased in patients receiving >10 years of DT. Similar results were also reported by Inoue et al. 7 and Chen et al., 23 albeit with smaller samples, and that included fewer patients receiving >10 years of DT. The present study is the largest to evaluate the correlation between duration of dialysis and bladder capacity, and we found 10 years of DT is a significant predictor of bladder atrophy.
The present study had several limitations. First, we used two different methods to measure the bladder capacity. Therefore, we compared the results between the two methods, and confirmed that the results were similar in 22 patients. Second, the timing of evaluation for VUR might have been too early. However, the best time to evaluate VUR is not well established. We routinely carried out voiding cystourethrography to evaluate VUR on day 4 post-transplant, when we remove the Foley catheter, so that it is less invasive for patients. In the present study, we observed 17 VURs at day 4 post-surgery. VURs persisted in 10 patients, seven of whom went on to develop pyelonephritis after transplantation. Therefore, VUR detected just after transplantation might be clinically significant. Finally, there was a selection bias related to the surgeon's preference. As this was a retrospective study, we could not clearly define which procedures were most effective in reducing the risk for UC in recipients with atrophic bladders.
In conclusion, we showed that bladder atrophy related to long-term DT increases the risk for urological complications after KT. Further prospective studies are required to determine which procedures are most effective for patients with atrophic bladders.
